Equitec Proprietary Markets’s Esperion Therapeutics ESPR Stock Holding History

Equitec Proprietary Markets’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,500	Closed	-$108K	–	66
2018 Q1	$108K	Buy	+1,500	New	+$110K	0.03%	47
2017 Q4	–	Sell	-400	Closed	-$21.5K	–	83
2017 Q3	$20K	Sell	400 -18	-4%	-$868	﹤0.01%	84
2017 Q2	$19K	Sell	418 -52,175	-99%	-$1.92M	﹤0.01%	99
2017 Q1	$1.86M	Buy	52,593 +50,659	+2,619%	+$1.16M	0.11%	37
2016 Q4	$24K	Buy	1,934 +1,334	+222%	+$15.9K	﹤0.01%	115
2016 Q3	$8K	Buy	600 +300	+100%	+$3.4K	﹤0.01%	130
2016 Q2	$3K	Sell	300 -1,000	-77%	-$16.6K	﹤0.01%	142
2016 Q1	$22K	Buy	1,300 +339	+35%	+$5.45K	﹤0.01%	128
2015 Q4	$21K	Buy	961 +461	+92%	+$11.6K	﹤0.01%	134
2015 Q3	$12K	Buy	+500	New	+$31.4K	﹤0.01%	157

Other funds holding ESPR

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return